The IT services firm strengthens its collaboration with Google Cloud to help enterprises move AI from pilot projects to production systems
Updated
March 17, 2026 1:02 AM
Google Cloud building. PHOTO: ADOBE STOCK
Enterprise interest in AI has moved quickly from experimentation to execution. Many organizations have tested generative tools, but turning those tools into systems that can run inside daily operations remains a separate challenge. Cognizant, an IT services firm, is expanding its partnership with Google Cloud to help enterprises move from AI pilots to fully deployed, production-ready systems.
Cognizant and Google Cloud are deepening their collaboration around Google’s Gemini Enterprise and Google Workspace. Cognizant is deploying these tools across its own workforce first, using them to support internal productivity and collaboration. The idea is simple: test and refine the systems internally, then package similar capabilities for clients.
The focus of the partnership is what Cognizant calls “agentic AI.” In practical terms, this refers to AI systems that can plan, act and complete tasks with limited human input. Instead of generating isolated outputs, these systems are designed to fit into business workflows and carry out structured tasks.
To make that workable at scale, Cognizant is building delivery infrastructure around the technology. The company is setting up a dedicated Gemini Enterprise Center of Excellence and formalizing an Agent Development Lifecycle. This framework covers the full process, from early design and blueprinting to validation and production rollout. The aim is to give enterprises a clearer path from the AI concept to a deployed system.
Cognizant also plans to introduce a bundled productivity offering that combines Gemini Enterprise with Google Workspace. The targeted use cases are operational rather than experimental. These include collaborative content creation, supplier communications and other workflow-heavy processes that can be standardized and automated.
Beyond productivity tools, Cognizant is integrating Gemini into its broader service platforms. Through Cognizant Ignition, enabled by Gemini, the company supports early-stage discovery and prototyping while helping clients strengthen their data foundations. Its Agent Foundry platform provides pre-configured and no-code capabilities for specific use cases such as AI-powered contact centers and intelligent order management. These tools are designed to reduce the amount of custom development required for each deployment.
Scaling is another element of the strategy. Cognizant, a multi-year Google Cloud Data Partner of the Year award winner, says it will rely on a global network of Gemini-trained specialists to deliver these systems. The company is also expanding work tied to Google Distributed Cloud and showcasing capabilities through its Google Experience Zones and Gen AI Studios.
For Google Cloud, the partnership reinforces its enterprise AI ecosystem. Cloud providers can offer models and infrastructure, but enterprise adoption often depends on service partners that can integrate tools into existing systems and manage ongoing operations. By aligning closely with Cognizant, Google strengthens its ability to move Gemini from platform capability to production deployment.
The announcement does not introduce a new AI model. Instead, it reflects a shift in emphasis. The core question is no longer whether AI tools exist, but how they are implemented, governed and scaled across large organizations. Cognizant’s expanded role suggests that execution frameworks, internal deployment and structured delivery models are becoming central to how enterprises approach AI.
In that sense, the partnership is less about new technology and more about operational maturity. It highlights how AI is moving from isolated pilots to managed systems embedded in business processes — a transition that will likely define the next phase of enterprise adoption.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.